Stewart H J, Forrest A P, Everington D, McDonald C C, Dewar J A, Hawkins R A, Prescott R J, George W D
Scottish Cancer Trials Office, Medical School, University of Edinburgh, UK.
Br J Cancer. 1996 Jul;74(2):297-9. doi: 10.1038/bjc.1996.356.
In 1985 a second randomisation was initiated for women in the treatment arm of the Scottish Tamoxifen Trial either to stop tamoxifen at 5 years or to continue indefinitely. A preliminary analysis of outcome in 342 patients at a median follow-up of 6 years suggests that a worthwhile gain in disease control from continuing adjuvant tamoxifen beyond 5 years is unlikely. [Hazard ratio for events (relapse or death without relapse) is 1.27, 95% CI = 0.87 - 1.85.] There is a suggestion that therapy for longer than 5 years may increase the risk of endometrial carcinoma (P = 0.064).
1985年，针对苏格兰他莫昔芬试验治疗组中的女性启动了第二次随机分组，她们被随机分为两组，一组在5年后停止服用他莫昔芬，另一组则无限期继续服用。对342名患者进行的初步分析显示，在中位随访6年时，5年后继续使用辅助性他莫昔芬在疾病控制方面不太可能获得显著益处。[事件（复发或无复发死亡）的风险比为1.27，95%置信区间 = 0.87 - 1.85。] 有迹象表明，治疗超过5年可能会增加子宫内膜癌的风险（P = 0.064）。
